Skip to main content
SpringerLink
Log in

What's new in CML? Highlights of ASH 2010

  • ASH Report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Chronic myeloid leukaemia (CML) is a paradigmatic disease, as knowledge on the molecular pathology of CML has driven the development of targeted drugs, which finally led to a substantial improvement of the patients' prognosis. However, despite very potent drugs, such as Imatinib, Nilotinib and Dasatinib for first- and second-line therapy are available, there is still place for improvement. Especially, selection of highly resistant T315I mutated clones represents a relevant clinical problem. The highlight of the 52nd Annual Meeting of the American Society (ASH) in 2010 for CML patients was data marking a profound step forward for patients developing a T315I mutation by providing safety and first efficacy results from a clinical trial testing Ponatinib, a TKI targeting T315I-mutated CML. These very early results from a small patient cohort provide a rationale basis for prospective testing of the drug in T315I-mutated CML and will help to further complement the "TKI cocktail" now available for CML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Druker B, Guilhot F, O'brien S, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23): 2408–2417, 2006

    Article  PubMed  CAS  Google Scholar 

  • Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91(4): 513–521, 2006

    PubMed  Google Scholar 

  • Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med, 362(24): 2251–2259, 2010

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 362(24): 2260–2270, 2010

    Article  PubMed  CAS  Google Scholar 

  • Gambacorti-Passerini C, Kim DW, Kantarjian H, Brummendorf TH, Dyagil I, Griskevicius L, et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. 52nd ASH Annual Meeting, 2010 (abstr. 208)

  • O'hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16(5): 401–412, 2009

    Article  PubMed  Google Scholar 

  • Cortes J, Talpaz M, Bixby D, Deininger M, Shah N, Flinn IW, et al. A Phase 1 trial of oral ponatinib (AP24534) in patients with refractory Chronic Myelogenous Leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. 52nd ASH Annual Meeting, 2010 (abstr. 210)

  • Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood, 112(10): 3965–3973, 2008

    Article  PubMed  CAS  Google Scholar 

  • Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol, 27(35): 6041–6051, 2009

    Article  PubMed  CAS  Google Scholar 

  • Yeung DT, Osborn M, White DL, Branford S, Haswell L, Slader C, et al. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDEL-II trial. 52nd ASH Annual Meeting, 2010 (abstr. 209)

  • Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 11(11): 1029–1035, 2010

    Article  PubMed  CAS  Google Scholar 

  • Hehlmann R, Jung-Munkwitz S, Lauseker M, Müller MC, Leitner A, Pletsch N, et al. Superior CMR-rates with tolerability-adapted Imatinib 800 mg vs. 400 mg vs. 400 mg + IFN in CML: the Randomized German CML-study IV. 52nd ASH Annual Meeting, 2010 (abstr. 357)

Download references

Author information

Authors and Affiliations

  1. Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria

    J. Rudzki & D. Wolf

  2. Laboratory for Tumorimmunology, Tyrolean Cancer Research Center, Innsbruck Medical University, Innsbruck, Austria

    J. Rudzki & D. Wolf

Authors
  1. J. Rudzki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Wolf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rudzki, J., Wolf, D. What's new in CML? Highlights of ASH 2010. memo 4, 124–126 (2011). https://doi.org/10.1007/s12254-011-0268-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-011-0268-1

Keywords

Search

Navigation